QIAGEN to develop QuantiFERON-TB Access as a new test for low-resource, high-burden regions in global fight against TB
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to develop a proprietary new version of a QuantiFERON®-based tuberculosis (TB) test dedicated and tailored to the needs of low-resource regions with a high disease burden of TB. The Mehr